Advertisement
ICLR vs IQV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICLR is a Hold and IQV is a Hold.
ICLR sees MACD Histogram crosses below signal line
ICLR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 01, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 34 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICLR as a result. In 65 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The 10-day moving average for ICLR crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 55 cases where ICLR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
ICLR moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICLR advanced for three days, in 203 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 156 of 220 cases where ICLR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. ICLR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.444) is normal, around the industry mean (72.578). P/E Ratio (270.092) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.533) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (1.626) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Momentum Indicator for IQV turns negative, indicating new downward trend
IQV saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned negative. In 49 of the 75 cases, the stock moved further down in the following days. The odds of a decline are at 65%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 60 cases where IQV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
Following a +1.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in 190 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
IQV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 108 of 226 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.225) is normal, around the industry mean (72.578). P/E Ratio (33.703) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
ICLR | IQV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 88 | 76 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 90 | 43 | |
PRICE GROWTH RATING 1..100 | 47 | 38 | |
P/E GROWTH RATING 1..100 | 2 | 18 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IQV's Valuation (65) in the Servicestothe Health Industry industry is in the same range as ICLR (83) in the Pharmaceuticals Other industry. This means that IQV’s stock grew similarly to ICLR’s over the last 12 months.
IQV's Profit vs Risk Rating (97) in the Servicestothe Health Industry industry is in the same range as ICLR (100) in the Pharmaceuticals Other industry. This means that IQV’s stock grew similarly to ICLR’s over the last 12 months.
IQV's SMR Rating (43) in the Servicestothe Health Industry industry is somewhat better than the same rating for ICLR (90) in the Pharmaceuticals Other industry. This means that IQV’s stock grew somewhat faster than ICLR’s over the last 12 months.
IQV's Price Growth Rating (38) in the Servicestothe Health Industry industry is in the same range as ICLR (47) in the Pharmaceuticals Other industry. This means that IQV’s stock grew similarly to ICLR’s over the last 12 months.
ICLR's P/E Growth Rating (2) in the Pharmaceuticals Other industry is in the same range as IQV (18) in the Servicestothe Health Industry industry. This means that ICLR’s stock grew similarly to IQV’s over the last 12 months.
| ICLR | IQV | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 69% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 65% |
| MACD ODDS (%) | 1 day ago 79% | N/A |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 71% |
| Advances ODDS (%) | 7 days ago 66% | 3 days ago 63% |
| Declines ODDS (%) | 14 days ago 70% | 8 days ago 64% |
| BollingerBands ODDS (%) | N/A | 1 day ago 74% |
| Aroon ODDS (%) | 1 day ago 71% | 1 day ago 48% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ICLR’s FA Score shows that 1 FA rating(s) are green while IQV’s FA Score has 1 green FA rating(s).
- ICLR’s FA Score: 1 green, 4 red.
- IQV’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ICLR’s TA Score shows that 4 TA indicator(s) are bullish while IQV’s TA Score has 4 bullish TA indicator(s).
- ICLR’s TA Score: 4 bullish, 4 bearish.
- IQV’s TA Score: 4 bullish, 2 bearish.
Price Growth
ICLR (@Medical Specialties) experienced а +2.98% price change this week, while IQV (@Medical Specialties) price change was +1.51% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.43%. For the same industry, the average monthly price growth was -0.17%, and the average quarterly price growth was +34.76%.
Reported Earning Dates
ICLR is expected to report earnings on Oct 27, 2026.
IQV is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Medical Specialties (-3.43% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement